Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
novel coronavirus inactivated vaccine
- Development stage
- Unknown
- Lead developer
- Sinopharm
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A type of vaccine used to prevent COVID-19 that contains SARS-CoV-2 virus particles that have been grown in culture and then killed (inactivated) using chemical means, such as beta-propiolactone. These vaccines, often produced in Vero cells, present the entire viral structure to the immune system, including the spike, membrane, envelope, and nucleocapsid proteins. They are typically formulated with an aluminum-based adjuvant to enhance immunogenicity. This platform has been the basis for several widely used vaccines, including those developed by Sinopharm and Sinovac, which have received emergency use listing or full approval in numerous countries.
- Brand names
- CoronaVacCOVILOHayat-VaxKCONVAC
- Other names
- Novel Coronavirus Inactivated Vaccine (Vero Cell)Inactivated SARS-CoV-2 vaccineCOVID-19 inactivated vaccineCOVID19 inactivated vaccineCOVID 19 inactivated vaccineSARS-CoV-2 inactivated vaccineSARS-CoV2 inactivated vaccineSARS-CoV 2 inactivated vaccine
02
Targets
SARS-CoV-2 spikeE (Tick-borne encephalitis virus envelope protein)N (Nucleocapsid protein)M protein (SARS-CoV-2 membrane protein)
Beyond the preview
Go deeper on novel coronavirus inactivated vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on novel coronavirus inactivated vaccine.